ML345 is a potent and selective NLRP3 inflammasome inhibitor with anti-inflammatory activity

Excessive activation of the NOD-like receptor pyrin domain–containing protein 3 (NLRP3) inflammasome plays a key role in the pathogenesis of various inflammatory diseases. Despite the development of several NLRP3 inhibitors, no specific therapy has been approved for clinical use, underscoring the urgent need for safe and effective agents. Here, we demonstrate that ML345 acts as a highly potent and selective NLRP3 inhibitor with strong therapeutic potential for NLRP3-driven inflammation. ML345 effectively suppresses canonical, noncanonical, and alternative NLRP3 inflammasome activation pathways, without affecting other inflammasomes. Mechanistically, ML345 blocks NLRP3 inflammasome activation independently of its intrinsic insulin-degrading enzyme (IDE) inhibitory activity. ML345 binds to NLRP3 in a non-covalent manner and directly targets tyrosine 381 (Y381), disrupting its essential interaction with NIMA-related kinase 7 (NEK7), consequently preventing inflammasome complex formation. In vivo, ML345 is well tolerated and markedly alleviates inflammatory responses and pathology in mouse models of NLRP3-associated disorders, including systemic inflammation and miscarriage triggered by lipopolysaccharide (LPS). Compared with several previously reported NLRP3 inhibitors, ML345 exhibits superior selectivity and comparable or greater inhibitory potency. These findings establish ML345 as a safe and selective NLRP3 inhibitor with robust anti-inflammasome effects and highlight its potential as a promising therapeutic candidate for NLRP3-driven diseases.

• Publication year

  2025

• Venue

  Molecular Biomedicine

• Publication date

  2025-11-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.1186/s43556-025-00363-7PMID 41231359PMCID 12615901
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mitochondria in oxidative stress, inflammation and aging: from mechanisms to therapeutic advances

  2025cited by this paper
• Targeting the NLRP3 inflammasome for inflammatory disease therapy

  2025cited by this paper
• Red blood cells undergo lytic programmed cell death involving NLRP3.

  2025cited by this paper
• Pyroptosis: molecular mechanisms and roles in disease

  2025cited by this paper
• Mechanistic insights into gasdermin-mediated pyroptosis

  2025cited by this paper
• Enrichment of decidual CD11c + CD8 + T cells with altered immune function in early pregnancy loss

  2025cited by this paper
• The role of inflammasomes in human diseases and their potential as therapeutic targets

  2024cited by this paper
• Inflammasome components as new therapeutic targets in inflammatory disease

  2024cited by this paper
• Inflammasomes in neurological disorders — mechanisms and therapeutic potential

  2024cited by this paper
• Pharmacological Inhibition of the NLRP3 Inflammasome: Structure, Molecular Activation, and Inhibitor-NLRP3 Interaction

  2023cited by this paper
• Entrectinib inhibits NLRP3 inflammasome and inflammatory diseases by directly targeting NEK7

  2023cited by this paper
• Biological and clinical roles of IL-18 in inflammatory diseases

  2023cited by this paper
• Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets

  2023cited by this paper
• A 360° view of the inflammasome: Mechanisms of activation, cell death, and diseases.

  2023cited by this paper
• Caspase-11 Interaction with NLRP3 Potentiates the Noncanonical Activation of the NLRP3 Inflammasome

  2022cited by this paper
• The NLRP3 inflammasome: activation and regulation.

  2022cited by this paper
• Structural Mechanisms of NLRP3 Inflammasome Assembly and Activation.

  2022cited by this paper
• Infections at the maternal–fetal interface: an overview of pathogenesis and defence

  2021cited by this paper
• An update on the regulatory mechanisms of NLRP3 inflammasome activation

  2021cited by this paper
• NLRP3 inflammasome in cancer and metabolic diseases

  2021cited by this paper
• RRx-001 ameliorates inflammatory diseases by acting as a potent covalent NLRP3 inhibitor

  2021cited by this paper
• Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial.

  2020cited by this paper
• NLRP3 inhibitors stoke anti-inflammatory ambitions

  2019cited by this paper
• Cell–cell contact with proinflammatory macrophages enhances the immunotherapeutic effect of mesenchymal stem cells in two abortion models

  2019cited by this paper
• Innate immunity to intracellular LPS

  2019cited by this paper
• Structural mechanism for NEK7-licensed NLRP3 inflammasome activation

  2019cited by this paper
• ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors).

  2018cited by this paper
• Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity

  2018cited by this paper
• Tranilast directly targets NLRP3 to treat inflammasome‐driven diseases

  2018cited by this paper
• Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders

  2017cited by this paper
• Inflammasome Complexes: Emerging Mechanisms and Effector Functions.

  2016cited by this paper
• Human Monocytes Engage an Alternative Inflammasome Pathway.

  2016cited by this paper
• Nek7 is an essential mediator of NLRP3 activation downstream of potassium efflux

  2016cited by this paper
• K+ Efflux-Independent NLRP3 Inflammasome Activation by Small Molecules Targeting Mitochondria.

  2016cited by this paper
• A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases

  2015cited by this paper
• Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death

  2015cited by this paper
• Inflammasome-independent regulation of IL-1-family cytokines.

  2015cited by this paper
• Noncanonical Inflammasome Activation by Intracellular LPS Independent of TLR4

  2013cited by this paper
• K⁺ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter.

  2013cited by this paper
• Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases

  2012cited by this paper
• A role for mitochondria in NLRP3 inflammasome activation

  2011cited by this paper
• Non-canonical inflammasome activation targets caspase-11

  2011cited by this paper
• Target identification using drug affinity responsive target stability (DARTS)

  2009cited by this paper
• Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization

  2008cited by this paper
• Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration

  2007cited by this paper
• Gout-associated uric acid crystals activate the NALP3 inflammasome

  2006cited by this paper
• Elucidating mechanisms of drug-induced toxicity

  2005cited by this paper

• No citing papers are available for this paper.